On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 1 Article 2
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 1, 08 January 2015
Rapid communications
First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014
  1. Epidemiology Area of the Autonomous Community of Madrid, General Directorate of Primary Care, Health Authority of the Autonomous Community of Madrid, Madrid, Spain
  2. Coordinating Centre for Health Alerts and Emergencies (CCAES),General Directorate of Public Health, Quality and Innovation, Madrid, Spain
  3. Subdirectorate of Health Prevention and Promotion, General Directorate of Primary Care, Health Authority of the Autonomous Community of Madrid, Madrid, Spain
  4. European Centre for Disease Prevention and Control (ECDC),Stockholm, Sweden
  5. The members of the group are listed at the end of the article

Citation style for this article: Lópaz MA, Amela C, Ordobas M, Domínguez-Berjón MF, Álvarez C, Martínez M, Sierra MJ, Simon F, Jansá JM, Plachouras D, Astray J, Working group of Ebola outbreak investigation team of Madrid. First secondary case of Ebola outside Africa: epidemiological characteristics and contact monitoring, Spain, September to November 2014. Euro Surveill. 2015;20(1):pii=21003. Article DOI:
Date of submission: 30 November 2014

On 6 October 2014, a case of Ebola virus disease (EVD) acquired outside Africa was detected in Madrid in a healthcare worker who had attended to a repatriated Spanish missionary and used proper personal protective equipment. The patient presented with fever <38.6 °C without other EVD-compatible symptoms in the days before diagnosis. No case of EVD was identified in the 232 contacts investigated. The experience has led to the modification of national protocols.


The current Ebola virus disease (EVD) epidemic affecting countries in West Africa is the largest ever registered outbreak of this disease [1]. Ongoing intensive transmission in the community and in healthcare facilities associated with weak health systems including limited human and material resources hinder adequate outbreak control and case management. Healthcare workers (HCW) in these areas have been significantly affected during this epidemic [2-5].

On 7 August 2014, the Spanish government decided to repatriate a Spanish missionary healthcare worker at the St. Joseph’s hospital in Monrovia (Liberia) who had tested positive for Ebola virus. On arrival, the person was admitted to the infectious diseases isolation unit at the reference hospital (La Paz-Carlos III Hospital Complex in Madrid). The patient remained hospitalised until his death on 12 August. On 22 September, a second Spanish missionary healthcare worker who had worked at a hospital in Lunsar (Sierra Leone) and who was also suffering from Ebola virus infection was repatriated under the same procedure. This patient was admitted to the same reference hospital where he died on 25 September. One of the HCW who was caring for the second repatriated Ebola case was diagnosed with EVD on 6 October. This was the first secondary case of this disease outside Africa.

In this paper we describe the epidemiological characteristics and public health control measures adopted after the identification of this first transmission outside the epidemic area. The information and lessons learnt in Spain may contribute to improving preparedness and response guidelines and protocols in non-affected countries. The risk of transmission of Ebola virus to healthcare professionals associated with repatriated patients needs to be reassessed and considered for future surveillance and control measures in these settings [5-7].

Epidemiological investigation and contact monitoring

Case description
The secondary case of EVD diagnosed in Spain on 6 October was one of the 117 HCW who had participated in the care of the two repatriated EVD cases. The HCW completed the 21-day monitoring period after caring for the first case on 30 August. On 21 and 25 September, she was exposed to the second patient and presumably contaminated fomites. She was classified as a low-risk contact and was therefore self-monitoring for symptoms, in accordance with the protocol [8]. The HCW had used appropriate personal protective equipment (PPE), i.e. waterproof long-sleeved clothing covering the feet, waterproof footwear, hood, face mask or goggles, double layer of gloves, and FP3 respirator [8], and she did not recall any incident during its use.

Following the established procedures for HCW caring for EVD patients [8], the hospital recommended self-monitoring for 21 days from 25 September onwards. According to these procedures, the HCW was supposed to inform the monitoring official at the hospital in case of fever >38.6 °C and any of the symptoms of the disease: severe headache, vomiting, diarrhoea, abdominal pain or bleeding. On the following day, 26 September, she was off duty. She contacted the monitoring official for the first time on 2 October.

Symptoms started on 29 September. She presented malaise and low-grade fever <38 °C. The grade fever remained at this level for three days and increased to 38 °C in the three following days [9]. Figure 1 shows the evolution and timeline of events.

Figure 1. Timeline of events for secondary Ebola case, Madrid, 24 September–27 November 2014

On 6 October at 04:00, she called the public health officials to report a temperature of 37.3°C, general malaise, nausea and cough. These symptoms led the public health officer to request medical evaluation at home and to refer her to the closest hospital. On admission at 07:00, she had a temperature of 36.7 °C, blood pressure of 90/60 mm Hg, 95% oxygen saturation measured by means of pulse oximetry, and a maculopapular rash. She reported that she had not received antipyretic agents [9]. At 08:00 on 6 October, the hospital contacted the public health services and they decided to classify the case as under investigation for EVD and send blood samples to the national reference laboratory. The patient’s condition worsened in the following hours [9] and at 18:00, the reference laboratory confirmed the diagnosis of EVD. The patient was transferred to the reference hospital under strict isolation measures. The patient received antiviral treatment and convalescent serum from a recovered Ebola patient. On 21 October, the case tested EVD-negative in two samples taken 48 hours apart and, according to protocols, was considered free of Ebola virus infection on 1 November when a PCR test of all body fluid samples yielded negative results. The isolation measures were suspended on the same day, and the patient was finally discharged on 5 November 2014.

Contact monitoring
The epidemiological investigation began at the time of diagnosis. Information on the patient’s possible exposure was requested and contact identification, risk classification and monitoring began at the same time. A committee of experts was established for the classification of contacts. High- and low-risk classification criteria and the action taken for each group are presented in Table 1. These actions were adapted from those established in the current protocol [8]. The first epidemiological information was provided by a family member of the patient at the hospital and was completed with available health and administrative records and the locations the patient reported to have visited from onset of symptoms until hospitalisation.

Table 1. Classification of contacts and public health measures adopted for the secondary Ebola case, Madrid 

A total of 232 contacts were identified, of whom 15 were classified as high-risk and 217 as low-risk (Table 2). Most contacts, excluding HCW at reference hospital, occurred on the day of diagnosis at the hospital where the diagnosis was established (Figure 2). The 15 contacts classified as high-risk were informed of the risks associated with their contact with the case and were recommended a quarantine, at a hospital facility if possible. All of them voluntarily agreed to undergo hospital quarantine for 21 days after the last exposure day.

Table 2. Number of contacts of the secondary Ebola case by exposure place, relationship with case and risk category (high risk contacts in brackets), Madrid, Spain, 29 September–27 November 2014 (n=232)

Figure 2. Number of contacts of the secondary Ebola case, by exposure date and risk categorya, Madrid, Spain, 29 September–9 October 2014 (n=87)

One of the low-risk contacts presented fever during the monitoring, but EVD was ruled out.

A total of 126 hospital employees were in contact with the patient during her stay at the hospital. Follow-up ended on 27 November, 21 days after the final exposure of the hospital cleaning staff. By that time, none of the contacts monitored had presented EVD.


Action protocols are based on the evidence obtained in the outbreak in Africa [9-11]. Early detection of cases for minimising the probability of transmission is the key aim of contact monitoring. However, when the first secondary case was diagnosed in Spain, the case definition provided in the existing national protocol and in most international protocols (European Centre for Disease Prevention and Control [12], United States (US) Centers for Disease Control and Prevention [13,14]) required a fever of >38.6 °C and symptoms compatible with the disease. This definition was not sensitive enough to detect this case in the first stages of disease. The non-specific clinical presentation of Ebola also makes early case detection difficult. This situation was also observed in the two secondary cases diagnosed a few days later in the US [15-17].

We would like to draw attention to the ‘paucisymptomatic’ presentation of EVD in infected contacts closely monitored after exposure to confirmed cases outside of the epidemic area in Africa not described up to now.

The public health measures applied immediately to the contacts of the secondary case in Madrid included active monitoring of low-risk contacts and quarantine for high-risk contacts. All contacts accepted these measures. However, in the future it may be necessary to apply the quarantine to more people or to contacts who refuse to be quarantined. In our opinion, it is necessary to develop procedures and laws which would establish and help apply the quarantine.

The experience with the repatriated cases in several non-epidemic countries and the secondary transmissions identified in Spain and in the US have resulted in proposals to modify existing protocols. These proposals [18] include increased sensitivity of the case definitions for persons under investigation in order to detect possible cases in the initial phases of the disease, particularly for contacts of confirmed cases, and a revision of contact classification and monitoring measures.

The Spanish experience highlights that the generation of secondary cases among HCW caring for repatriated EVD patients represents the currently main risk for Europe as has happened also in US [8,13-15]. The risk is very low, however it can not be excluded [19].

Despite the existence of preparedness and response plans, trained professional teams, 24/7 alert systems and contingency plans for control and response of communicable diseases in both hospitals, the number of exposed contacts among HCW was high. After the secondary case was diagnosed, training and assessment was reinforced for all healthcare professionals involved in the treatment and care of EVD and a committee was set up to classify incidents. This alert shows the need for constant updating and training of professionals in the use of PPE and strict application of donning and doffing procedures in order to minimise the risks. Hence it is necessary to provide adequate risk communication and create awareness in HCW who care for these patients.

Despite the rapid activation of the protocols and control measures, this first case of secondary transmission of EVD outside Africa has represented an unprecedented challenge for the health services and public health authorities in Spain [9,12-14] and has highlighted the need to strengthen continuous preparation and training in order to respond properly to this type of emergency.

We would like to thank all the clinicians, informatics and laboratory workers involved in the management of the outbreak.

Conflict of interest
None declared.

Authors’ contributions
Jenaro Astray and Mª Ángeles Lópaz wrote the first draft of the manuscript. Mª Ángeles Lópaz managed the Ebola outbreak alert system, Jenaro Astray coordinated the Ebola response team of the Community of Madrid and acted as a liaison to the reference hospital, Maria Ordobás was responsible for contact monitoring, Felicitas Dominguez managed the alert information system, Carmen Álvarez and Manuel Martínez led the Ebola Crisis Committee. Carmen Amela, Mª José Sierra and Fernando Simón coordinated the Ebola response at the national level, and Carmen Amela also participated in the regional Ebola response team. Josep Jansa and Diamantis Plachouras participated in the contact classification and assessment. The working group participated in the fieldwork, conducting epidemiological survey, classifying cases and contact monitoring. All authors critically read and revised the drafts of the manuscripts.

Members of the working group of the Ebola outbreak investigation team of Madrid
Aguirre R, Aragón A, Arce A ,Camarero M, Córdoba E, Cuevas I, Domínguez MJ, García J, García-Comas L, Garcia N, Gascón MJ, Hernando M, Ibáñez C, Insua E, Jiménez S, Lasheras MD, Méndez I, Moratilla L, Navea A, Noguerales R, Nováková V, Ortiz H, Rodero I, Rodríguez E, San Miguel L, Taveira J A, Sanchez A, Santos S, Suarez B, Torijano MJ, Valcárcel MA, Velasco M, Zorrilla B.


  1. WHO Ebola Response Team. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med. 2014;371(16):1481-95. PMID:25244186
  2. Poletto C, Gomes M, Pastore Y, Piontti A, Rossi L, Bioglio L, Chao D, et al. Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic. Euro Surveill.2014;19(42):20936. PMID:25358040
  3. Fitzpatrick G, Vogt F, MoiGbabai O, Black B, Santantonio M, Folkesson E, et al. Describing readmissions to an Ebola case management centre (CMC), Sierra Leone, 2014. Euro Surveill.2014;19(40):20924. PMID:25323075
  4. Fasina FO, Shittu A, Lazarus D, Tomori O, Simonsen L, Viboud C, et al. Transmission dynamics and control of Ebola virus disease outbreak in Nigeria, July to September 2014. Euro Surveill.2014;19(40):20920. PMID:25323076
  5. Sprenger M, Coulombier D. Preparedness is crucial for safe care of Ebola patients and to prevent onward transmission in Europe - outbreak control measures are needed at its roots in West Africa. Euro Surveill.2014;19(40):20925. PMID:25323074
  6. Infection prevention and control recommendations for hospitalized patients with known or suspected Ebola virus disease in U.S. hospitals. Atlanta: Centers for Disease Control and Prevention; Nov 2014. Available from:
  7. Wiwanitkit V. Ebola, fear and preparedness. Epidemiol Health. 2014;36:e2014015. doi: 10.4178/epih/e2014015. PMID: 25220146.
  8. Protocolo de actuación frente a casos sospechosos de enfermedad por virus ébola (eve). [Protocol for actionagainst suspected cases of Ebola virus disease]. Madrid: Ministry of Health,Social Services and Equality; 15 Sep 2014. Spanish. Available from:
  9. Parra JM, Salmerón OJ, Velasco M. The First case of Ebola virus disease acquired outside Africa. N Engl J Med. 2014. PMID: 25409262.
  10. Forrester JD, Pillai SK, Beer KD, Neatherlin J, Massaquoi M, Nyenswah TG, et al. Assessment of ebola virus disease, health care infrastructure, and preparedness - four counties, Southeastern Liberia, august 2014. MMWR Morb Mortal Wkly Rep. 2014;63(40):891-3. PMID:25299605
  11. Benowitz I, Ackelsberg J, Balter SE, Baumgartner JC, Dentinger C, Fine AD, et al. Surveillance and preparedness for Ebola virus disease—New York City, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(41):934-6. PMID:25321072
  12. McCarty CL, Basler C, Karwowski M, Erme M, Nixon G, Kippes C, et al. Response to importation of a case of ebola virus disease - ohio, october 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1089-91. PMID:25412070
  13. European Centre for Disease Prevention and Control (ECDC). Ebola virus disease case definition for reporting in EU. Stockholm: ECDC. [Accessed:  21 Nov 2014]. Available from:
  14. Centers for Disease Control and Prevention (CDC).Ebola virus disease information for clinicians in U.S. healthcare settings. Atlanta: CDC. [Accessed 21 Nov 2014]. Available from:
  15. Centers for Disease Control and Prevention (CDC). Risk of Exposure. Atlanta: CDC. [Accessed: 21 Nov 2014]. Available from:
  16. Chevalier MS, Chung W, Smith J, Weil LM, Hughes SM, Joyner SN, et al. Ebola virus disease cluster in the United States - dallas county, Texas, 2014. MMWR Morb Mortal Wkly Rep. 2014;63(46):1087-8. PMID:25412069
  17. Centers for Disease Control and Prevention (CDC). Cases of Ebola diagnosed in the United States. Atlanta: CDC. [Accessed: 21 Nov 2014]. Available from:
  18. Protocolo de actuación frente a casos sospechosos de Enfermedad por virus ébola (EVE). [Protocol for action against suspected cases of Ebola virus disease]. Madrid: Ministry of Health, Social Services and Equality; 13 Oct 2014. Spanish. Available from:
  19. Evaluación del riesgo para España de la epidemia de fiebre hemorrágica por el virus de Ébola en África Occidental. [Risk assessment Spain epidemic hemorrhagic fever virus Ebola in West Africa]. Madrid: Ministry of Health, Social Services and Equality; 9 Dec 2014. Spanish. Available from:

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.